1. What is Zimmerman Biopharmaceutical?
ZBP is a biopharmaceutical company that has developed a proprietary technology to manufacture insulin and insulin analog-active pharmaceutical ingredients. Our technology simplifies and accelerates the production process, making our insulin and insulin analogs cost-competitive on a global scale. 
  1. What are the company’s goals?
ZBP’s goal is to become a global manufacturer of integrated and biosimilar medicines by leveraging our expertise in protein manufacturing. 
  1. How do you expect to accomplish your goals?
ZBP is actively working on receiving all necessary FDA approvals to market our products. Our business strategy includes developing a world-class facility that will manufacture insulin and insulin analogs using ZBP’s proprietary technology in compliance with Good Manufacturing Practices (cGMP).
  1. What are your sales and marketing strategies?
In the U.S., we will commercialize our insulin and insulin analogs through in-house sales and marketing teams. Outside the U.S., we will secure selective partnerships and seek regulatory approvals to manufacture and to distribute our products.
  1. Why now? What’s going on with insulin that I need to be aware of?
The insulin market has not experienced a significant innovation for decades. In the United States and Europe, three major pharmaceutical companies have enjoyed exclusive marketing rights for their insulin products because of strictly enforced intellectual property laws. During this time, insulin product improvements were limited mostly to new delivery and absorption mechanisms such as controlled-dosage pens, extended-release and inhalable insulin products. However, these innovations were largely accompanied by significant price increases. During 2012-2016, a substantial number of patents from major insulin manufacturers expired. This has given ZBP a pathway to seek approval for its biosimilar products and to enter the marketplace with low-cost insulin.
  1. Can you tell me more about your process?
ZBP has proprietary process technology for making biosimilar insulin and insulin analogs resulting in significantly lower costs and a go-to-market plan that is faster than existing manufacturing processes. 
  1. Tell me about the FDA process.
The type of FDA regulatory process we are approved for promises an accelerated path to market and allows for revenues in 24-30 months after our capital raise. 
  1. Do you hold any patents?
No. However, ZBP owns the rights to our proprietary process and there are no other owners nor patent holders of our process.
  1. Tell me more about the company’s upside potential?
We expect ZBP’s portfolio of human insulin, fast acting insulin, glucagon, glargine will become the product of choice in a marketplace that lacks competition and is known for high end-user prices. 
  1. What is the market for your products?
ZBP’s products will first target the global insulin market which was valued at $42.9 billion in 2017 and is expected to reach a market size of $70.6 billion by 2023. Being a cost-leader in this marketplace will enable ZBP to effectively achieve rapid and deep market penetration.
  1. Do you have FDA approval?
Not yet. However, ZBP is aggressively pursuing regulatory approvals for its insulin and insulin analogs. 
  1. Who is leading the company?
ZBP’s management has extensive experience in the biopharmaceutical and drug manufacturing industry with a demonstrated track record in delivering products through FDA.

Dr. Ron Zimmerman has over 40 years of experience in the protein chemistry field and more than 15 years of working on insulins.

Mr. David Wood has over 35 years of leadership experience with nearly 20 years in executive leadership roles that involved creation of substantial shareholder value.

Ms. Donna Zimmerman has over 30 years of experience in the clinical area monitoring clinical trials, managing FDA approval processes, Investigational New Drug (IND) application process and New Drug Application (NDA) process.
  1. Are you raising money right now?
Yes! We are actively raising capital to bring our products to market. Please contact us at if you are interested in participating as an investor.

LAST UPDATED: November 20, 2019

Get updates on latest news

Fill out my online form.

Contact Us

We appreciate your interest in our company. A ZBP representative will respond at the first available opportunity.
Fill out my online form.
Contact Us
Back to Top of Page